We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.
We are looking for D/P's in the following categories:
| ID # | Required D/P's | Enrolled D/P's | Remaining D/P's | Inclusion Criteria |
|---|---|---|---|---|
| 280242 | 20 | 0 | 20 | Prospective Matched Set Collection from HxV Negative Donors (Roche cfDNA tube, K2EDTA plasma and PDB) |
| 280237 | 5 | 0 | 5 | Prospective Whole Blood Collection from HxV Negative Donors (Paxgene RNA tubes) |
| 279827 | 6 | 40 | -34 | Pre-Selected HCV RNA Negative Serum Samples from Inventory |
| 279806 | 2 | 2 | 0 | Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load |
| 279381 | 40 | 40 | 0 | Pre-Selected HxV Negative Serum Samples From Inventory |
| 278992 | 5 | 5 | 0 | Pre-Selected SARS-CoV-2 Positive Samples From Inventory |
| 278976 | 100 | 102 | -2 | Prospective Sars-Cov-2 , Flu A, Flu B and RSV Samples Collection_TCZ0006755 / SRF_0002812 |
| 277709 | 30 | 0 | 30 | Pre-Selected Gonorrhea Positive Samples from Inventory (Urine) |
| 277708 | 30 | 4 | 26 | Pre-Selected Chlamydia Positive Samples from Inventory (Urine) |
| 277707 | 20 | 20 | 0 | Whole Blood from Healthy Individuals |
| 277324 | 30 | 30 | 0 | Pre-Selected RPR Positive Samples from Inventory |
| 277322 | 30 | 30 | 0 | Pre-Selected Gonorrhea Positive Samples from Inventory |
| 277321 | 30 | 30 | 0 | Pre-Selected Chlamydia Positive Samples from Inventory |
| 277320 | 30 | 30 | 0 | Pre-Selected HBsAg Positive Samples from Inventory |
| 277319 | 30 | 30 | 0 | Pre-Selected HIV Positive Samples from Inventory |
| 277318 | 30 | 30 | 0 | Pre-Selected HCV Positive Samples from Inventory |
| 277194 | 5 | 5 | 0 | Pre-Selected Na Citrate plasma HxV Negative Samples From Inventory |
| 277014 | 10 | 10 | 0 | High Volume Plasma Collection from HxV Negative Donors - TZC0010364/SRF_0002851 |
| 276588 | 6 | 6 | 0 | RMS SARS-CoV-2 Samples for Heat Inactivation |
| 276575 | 500 | 217 | 283 | Pre-Selected Syphilis Positive / Reactive Samples from Inventory |
| 276035 | 6 | 6 | 0 | Pre-Selected HxV Negative Samples From Inventory |
| 276033 | 200 | 166 | 34 | Collection protocol for Panel construction (Custom HIV-1 panels, Q_16975) |
| 275984 | 8 | 8 | 0 | HIV Positive Stability Study |
| 275841 | 14 | 8 | 6 | Pre-Selected Chlamydia Positive Samples from Inventory |
| 275098 | 55 | 55 | 0 | Prospective Whole Blood Collection from HxV Negative Female D/Ps |
| 275091 | 200 | 187 | 13 | Pre-Selected HBsAg Samples with Viral Load from Inventory |
| 274652 | 100 | 115 | -15 | Prospective SARS-CoV-2 Negative Sample Collection Protocol |
| 274509 | 200 | 138 | 62 | Pre-Selected HxV Negative Samples From Inventory |
| 273311 | 3 | 3 | 0 | K2EDTA Plasma and PDB from Healthy (HxV Negative) D/Ps - TZC0008969/ SRF_0002832 |
| 272798 | 12 | 12 | 0 | High Volume Whole Blood Collection from HxV Negative D/Ps - TZC0008853 / SRF_0002839 |
| 272790 | 2 | 2 | 0 | Pre-Selected Dual Infected Urine Samples from Inventory |
| 272779 | 20000 | 1795 | 18205 | Disposition of Negatives Whole Blood samples fron Freezer 48 (talent samples) |
| 272609 | 5 | 1 | 4 | HIV-1 Positive Prospective Blood Collection Protocol - 2 D/Ps with Viral Load over 2,000 cp/mL - 1 D/P with Viral Load at around 1,000 cp/mL - 1 D/P with Viral Load at around 2,000 cp/mL - 1 D/P with Viral Load at around 3,000 cp/mL |
| 272408 | 2000 | 91 | 1909 | Disposition of Samples from JRs 140667 |
| 272195 | 24 | 24 | 0 | Female Vaginal Sample Collection Protocol for Panel Development |
| 272143 | 400 | 308 | 92 | Pre-Selected HBV Positive Samples from Inventory with Viral Load and Genotype |
| 271914 | 100 | 6 | 94 | COVID-19 Testing; Private Office |
| 271841 | 25 | 17 | 8 | Pre-Selected anti-HBs Samples from Inventory |
| 271644 | 9 | 8 | 1 | Prospective Whole Blood Collection from HxV Negative D/Ps |
| 271463 | 800 | 0 | 800 | Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Las Vegas |
| 271462 | 800 | 0 | 800 | Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Northridge |
| 271164 | 2 | 1 | 1 | High Volume Whole Blood Units from Healthy Donors (Sodium Citrate) - TZC0007529 |
| 270405 | 6 | 4 | 2 | Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load |
| 270404 | 7 | 2 | 5 | Pre-Selected HBV Positive Samples from Inventory with Viral Load |
| 269024 | 2 | 3 | -1 | Negative Serum samples for HBV Panels_16894 |
| 268387 | 7 | 2 | 5 | Pre-Selected HIV-1 Positive Samples from Inventory with Viral Load |
| 268012 | 35 | 35 | 0 | SARS-CoV-2 Testing (Abbott) |
| 267478 | 2 | 0 | 2 | High Volume Whole Blood Units from Healthy Donors - INC5087530 |
| 267417 | 50 | 46 | 4 | Prescreaning collection for JR 236653 (HIV Positive DPs, Viral Load 1000-8000) |
| 267180 | 1500 | 123 | 1377 | Prospective Healthy Subject Blood Collection Protocol |
| 266931 | 120 | 17 | 103 | PAS-19SUST053 Testing HBV VL (Abbott & Hologic) |
| 266866 | 120 | 25 | 95 | Protocol: FD-001 - Clinical Evaluation of the Fosun COVID-19 Ag Home Test In Symptomatic and Asymptomatic Subjects |
| 266841 | 2000 | 412 | 1588 | Disposition of BioRepository Samples from JRs 200854 and 235406_Phase Scientific_Felix Chao |
| 264837 | 45 | 45 | 0 | SARS-CoV-2 Testing (Abbott and Hologic) |
| 263501 | 100 | 29 | 71 | Protocol: ZPT-001 - Clinical Performance of the Zepto SARS-CoV-2 IgG Self Test In Subjects who are Symptomatic and Asymptomatic from COVID-19 Infection |
| 262723 | 50 | 34 | 16 | Pre-Selected HAV Samples from Inventory |
| 262559 | 27 | 22 | 5 | Pre-Selected HIV-1 Positive Samples from Inventory with Viral Load, Group and Subtype |
| 262552 | 200 | 192 | 8 | Pre-Selected HBsAg Serum Samples from Inventory |
| 261154 | 800 | 1877 | -1077 | Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation |
| 260890 | 200 | 206 | -6 | K2EDTA Plasma and PDB from Healthy (HxV Negative) D/Ps - TZC0004044/SRF_0002722 |
| 260425 | 2000 | 4338 | -2338 | Disposition of BioRepository Samples - Lav/Yellow Tubes |
| 259067 | 100 | 50 | 50 | Clinical Evaluation of the Visby Medical Respiratory Health Test for the Detection and Differentiation of SARS-CoV-2, Influenza A and Influenza B Viral RNA - Clinical Protocol TP-000547 |
| 256987 | 15 | 0 | 15 | Pre-Selected SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory |
| 254791 | 1000 | 15 | 985 | COVID-19 Testing; Private Office |
| 254733 | 3 | 4 | -1 | Negative Serum samples for HBV Panels_16894 |
| 253783 | 9 | 6 | 3 | Prospective Whole Blood Collection from HxV Negative D/Ps |
| 251350 | 100 | 22 | 78 | SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol |
| 249722 | 5 | 2 | 3 | Fresh Whole Blood from Healthy (HxV Negative) D/Ps with MTS - INC4998359 |
| 248874 | 200 | 200 | 0 | Normal Serum and Plasma Samples for Panels_Q_16847 |
| 245699 | 20 | 0 | 20 | Pre-Selected HBV Samples with Viral Loads between 1,000 - 10,000,000 IU/mL |
| 244616 | 1700 | 1739 | -39 | SARS-CoV-2 Hologic Aptima Testing |
| 244149 | 16 | 15 | 1 | Normal Serum and Plasma Samples for Panels_Q_16847 |
| 243774 | 60 | 0 | 60 | Pre-Selected BKV and EBV Negative Plasma Samples from Inventory - SRF_0002565 |
| 243767 | 450 | 0 | 450 | Pre-Selected BKV and EBV Positive Plasma and Urine Samples from Inventory - SRF_0002565 |
| 242730 | 100 | 276 | -176 | Abbott RealTime CT/NG Testing - Protocol 248B1 |
| 242729 | 300 | 262 | 38 | Vaginal Sample Collection Protocol - Donors with Vaginitis Symptoms |
| 242206 | 5000 | 24662 | -19662 | COVID-19 Testing |
| 241492 | 500 | 40 | 460 | Protocol: OQ-COV-PA2 - InteliSwab COVID-19 Rapid Test - 2nd visit |
| 239962 | 500 | 41 | 459 | Protocol: OQ-COV-PA2 - InteliSwab COVID-19 Rapid Test |
| 239950 | 1000 | 40 | 960 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami |
| 239188 | 500 | 0 | 500 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 237354 | 1 | 1 | 0 | Pre-Selected BKV and EBV Positive Plasma Samples from Inventory (Dual Infection) |
| 237350 | 5 | 2 | 3 | Pre-Selected BKV Positive Plasma Samples from Inventory |
| 237091 | 11 | 0 | 11 | Fresh Whole Blood from Healthy Individuals |
| 236653 | 5 | 2 | 3 | HIV-1 Positive Prospective Blood Collection Protocol - 2 D/Ps with Viral Load over 2,000 cp/mL - 1 D/P with Viral Load at around 1,000 cp/mL - 1 D/P with Viral Load at around 2,000 cp/mL - 1 D/P with Viral Load at around 3,000 cp/mL |
| 235480 | 19 | 0 | 19 | Pre-Selected Chlamydia Positive Samples from Inventory (Serum and Plasma) |
| 235406 | 300 | 74 | 226 | SARS-CoV-2 RNA Hologic Testing (Felix Chao and Peter Kim) |
| 234803 | 200 | 198 | 2 | Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16976) |
| 234090 | 17 | 0 | 17 | Pre-Selected anti-HBs Positive Samples from Inventory |
| 233218 | 150 | 8 | 142 | IDS-21MAXCOMBO - SARS-CoV-2 Hologic Aptima Testing |
| 233007 | 1000 | 27 | 973 | CBC Initiative, SACQ_0002392 (INC4932295) - SRF_0002617 - Buffy Coat - BCW |
| 231203 | 100 | 36 | 64 | Clinical Evaluation of Visby Medical Personal PCR Women’s Sexual Health Test for the Detection of CT, GC and TV using self-collected Vaginal Swabs - Protocol TP-000669 |
| 231202 | 53 | 53 | 0 | Beta Study of the Visby Sexual Health Test - Clinical Protocol TP-000516 |
| 230530 | 20000 | 1295 | 18705 | Customer Samples kept in Biorepository (CMVG Samples, Susan Rimpel) |
| 228548 | 100 | 102 | -2 | Remnant VZV Samples (IGG Negative) |
| 228201 | 20000 | 466 | 19534 | Customer Samples kept in Biorepository from Minneapolis Medical Research Foundation (MMRF) |
| 227994 | 130 | 5 | 125 | PAS-19SUST054 - HCV |
| 227993 | 130 | 1 | 129 | PAS-19SUST052 - HBV |
| 227992 | 130 | 10 | 120 | PAS-18SUST041 - Evaluation of the BD Vacutainer® K2EDTA Blood Collection Tubes with Hemogard™ Closure using Molecular Diagnostic Testing for HIV-1 Viral Load (VL) Assay |
| 227621 | 3 | 2 | 1 | HIV-1 Positive Prospective Blood Collection Protocol: - Three (3) D/Ps to have an HIV-1 Viral Load of: Donor #1: 1000 copies/mL (+/- 10%) Donor #2: 2000 copies/mL (+/- 10%) Donor #3: 3000 copies/mL (+/- 10%) |
| 226001 | 100 | 38 | 62 | SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol |
| 225611 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 225101 | 1000 | 9 | 991 | COVID-19 Testing; Private Office |
| 224701 | 360 | 0 | 360 | cX8-COV-549: Classic Repro Protocol |
| 224514 | 600 | 76 | 524 | Initiative to Screen Potential Study Candidates (SUST) |
| 222843 | 20 | 0 | 20 | Remnant SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory |
| 220541 | 100 | 42 | 58 | Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16913) |
| 219607 | 1000 | 13 | 987 | COVID-19 Testing; Private Office |
| 219219 | 22 | 21 | 1 | Normal Serum and Plasma Samples for Panels_Q_16894, Q_16914 and Q_16913 |
| 217882 | 65 | 12 | 53 | Prospective SARS-CoV-2 Positive Sample Collection Protocol (NPS and Saliva) |
| 213622 | 2500 | 0 | 2500 | Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study |
| 210071 | 2500 | 555 | 1945 | Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study |
| 208168 | 1000 | 111 | 889 | COVID-19 Testing; Private Office |
| 205506 | 200 | 0 | 200 | Urine and Saliva Matched Set from Healthy D/Ps -100 subject collected in the morning until 9 AM -100 subjects collected in the afternoon after 4 PM |
| 205083 | 10 | 0 | 10 | Prospective Urine Collection from Healthy Donors |
| 202732 | 1000 | 99 | 901 | PROTOCOL 274C3 - Clinical Evaluation of the Xpert® Xpress CoV-2/Flu/RSV XC Test on the GeneXpert Dx and Infinity Systems in Laboratory and Near-Patient Testing Environment |
| 201758 | 130 | 48 | 82 | PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay |
| 200508 | 1000 | 60 | 940 | COVID-19 Testing; Private Office |
| 198399 | 220 | 0 | 220 | Prospective SARS-CoV-2 Collection from Symptomatic D/Ps |
| 198391 | 500 | 0 | 500 | Prospective Healthy Subject Blood Collection Protocol |
| 195801 | 220 | 0 | 220 | Prospective SARS-CoV-2 Collection from Symptomatic D/Ps |
| 195775 | 20000 | 1380 | 18620 | Customer Samples kept in Biorepository from HBcT2 [JRID#93116] |
| 193266 | 200 | 130 | 70 | Prospective SARS-CoV-2 Collection from Symptomatic D/Ps |
| 190737 | 5000 | 23 | 4977 | SARS-CoV-2 Survey (PT) |
| 184026 | 700 | 542 | 158 | SARS-CoV-2 RNA Hologic Testing |
| 182696 | 1000 | 355 | 645 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections |
| 180141 | 15 | 15 | 0 | Normal Serum and Plasma Samples for Panels_Q_16847 |
| 178076 | 130 | 79 | 51 | PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay |
| 175884 | 500 | 97 | 403 | SARS-CoV-2 RNA Hologic Testing |
| 175792 | 10000 | 116 | 9884 | COVID-19 Testing; Tu Cara me Sue |
| 175398 | 10000 | 552 | 9448 | COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd |
| 175121 | 1000 | 27 | 973 | CBC Initiative |
| 174026 | 1000 | 122 | 878 | COVID-19 Testing; Private Office |
| 173768 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Saliva, Sputum, Nasal, Pharyngeal, Blood and/or Finger Stick Specimens from SARS-CoV-2 positive subjects |
| 173505 | 20 | 20 | 0 | SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory |
| 172886 | 1000 | 1018 | -18 | COVID-19 Testing; Private Office |
| 169711 | 400 | 398 | 2 | SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva |
| 169440 | 300 | 110 | 190 | Remnant Pregnancy Samples |
| 169439 | 100 | 258 | -158 | Remnant HSV Samples |
| 168884 | 50 | 0 | 50 | Evaluation of the prognostic performance of HostDx ViralSeverity to predict outcomes of SARS-CoV-2 |
| 168867 | 1000 | 345 | 655 | COVID-19 Testing; Private Office |
| 168264 | 10 | 10 | 0 | SARS-CoV-2 Negative Nasal, Nasopharyngeal Swab |
| 168078 | 50 | 2 | 48 | Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva) |
| 165868 | 1000 | 156 | 844 | COVID-19 Testing; Private Office |
| 163904 | 1000 | 1000 | 0 | COVID-19 Testing; Private Office |
| 162417 | 35 | 34 | 1 | Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5868_4 |
| 161853 | 100 | 861 | -761 | Abbott RealTime CT/NG Testing, Cepheid_248C1& 248C3 |
| 157934 | 1000 | 803 | 197 | COVID-19 Testing; Private Office |
| 156661 | 10000 | 1756 | 8244 | COVID-19 Testing; Private Office |
| 155679 | 30 | 313 | -283 | SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol |
| 154904 | 10000 | 40 | 9960 | COVID-19 Testing; Private Office |
| 154536 | 1000 | 458 | 542 | Cerebral Spinal Fluid (CSF) Unit from Live D/Ps - Minimum total volume of 500 ml required - Individual samples of at least 0.25 ml - The samples must have no trace of hemolysis (red color). - Stored under -80°C. - Remnant material acceptable - No IRB nor Informed Consent needed - No clinical history - Custom Manifest file |
| 153900 | 10000 | 31302 | -21302 | COVID-19 Testing, Florida Department of Health |
| 152854 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 152825 | 5000 | 106640 | -101640 | COVID-19 Testing |
| 152672 | 5000 | 40 | 4960 | Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs |
| 152645 | 24 | 0 | 24 | Female Vaginal Sample Collection Protocol for Panel Development |
| 152331 | 5000 | 1654 | 3346 | COVID-19 Testing |
| 151681 | 5000 | 3 | 4997 | Refer to Processing Instructions @ Attachment Tab |
| 151476 | 1 | 0 | 1 | HIV Group and Subtype Testing |
| 150014 | 500 | 64 | 436 | Seegene Validation Collection Protocol from Male and Female Samples |
| 149547 | 5000 | 220 | 4780 | Refer to Processing Instructions @ Attachment Tab TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB |
| 149267 | 200 | 347 | -147 | Prospective Nasopharyngeal Swab Collection- SRF_5469 |
| 148791 | 5000 | 32 | 4968 | Refer to Processing Instructions @ Attachment Tab |
| 146391 | 92 | 0 | 92 | High Volume Whole Blood Collection to Evaluate The Long-Term Stability of Roche cfDNA tubes - SRF_5743 |
| 145574 | 5000 | 80 | 4920 | Refer to Processing Instructions @ Attachment Tab |
| 144620 | 5000 | 41 | 4959 | Refer to Processing Instructions @ Attachment Tab |
| 144001 | 100 | 825 | -725 | Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM): - 50 samples from subjects with the ages of 2 through 12 years of age AND - 50 samples from subjects with the ages of 13 through 21 years of age - Gender: Male or Female - Minimum Volume: 1.5 mL (1.2 mL's) - Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection. |
| 143401 | 1500 | 1158 | 342 | Cerebral Spinal Fluid (CSF) Unit from Live D/Ps - Minimum total volume of 3000 ml required - Individual samples of at least 0.25 ml - The samples must have no trace of hemolysis (red color). - Stored under -80°C. - Remnant material acceptable - No IRB nor Informed Consent needed - No clinical history - Custom Manifest file |
| 142755 | 5000 | 80 | 4920 | Refer to Processing Instructions @ Attachment Tab |
| 141914 | 1000 | 7 | 993 | HIV Initiative |
| 141493 | 5000 | 40 | 4960 | HCV Viral Load and Genotype Survey (PT) |
| 141491 | 5000 | 18 | 4982 | HBV Viral Load Survey (PT) |
| 141490 | 5000 | 40 | 4960 | HIV Viral Load Survey (PT) |
| 140923 | 5000 | 80 | 4920 | Refer to Processing Instructions @ Attachment Tab |
| 140922 | 5000 | 45 | 4955 | Refer to Processing Instructions @ Attachment Tab |
| 140530 | 5000 | 10 | 4990 | Rubella IgG (AAB - PT) |
| 140528 | 5000 | 6 | 4994 | ToRCH (AAB - PT) |
| 139409 | 5000 | 85 | 4915 | Pregnancy (PT) |
| 137933 | 5000 | 0 | 5000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
| 137683 | 930 | 235 | 695 | Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations |
| 136025 | 300 | 357 | -57 | EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM) |
| 135041 | 100 | 0 | 100 | GC/CT/MG/TV prospective collection at Budapest |
| 134182 | 100 | 80 | 20 | HBV/Mayaro Samples from Colombia |
| 133225 | 200 | 274 | -74 | Prospective HCV Positive serum collection |
| 129688 | 200 | 123 | 77 | EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia |
| 129538 | 1000 | 309 | 691 | RPR Initiative |
| 128402 | 1000 | 64 | 936 | CBC Initiative |
| 124266 | 5000 | 143 | 4857 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire |
| 122931 | 5000 | 1510 | 3490 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 122654 | 5000 | 171 | 4829 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland |
| 120851 | 140 | 26 | 114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 120409 | 300 | 84 | 216 | Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population |
| 109382 | 100 | 32 | 68 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
| 109381 | 300 | 6 | 294 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 108692 | 1000 | 958 | 42 | HxV Testing Initiative |
| 102772 | 50 | 26 | 24 | Random Cadaveric Samples |
| 102419 | 1000 | 452 | 548 | Samples on hold for future shipments to China |
| 98830 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples |
| 98084 | 1000 | 562 | 438 | CBC Qualifying Job Request |
| 96278 | 195 | 185 | 10 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 96055 | 40 | 1732 | -1692 | Hologic Panels for HIV and HCV |
| 94841 | 500 | 1 | 499 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR |
| 93116 | 700 | 734 | -34 | Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis |
| 80997 | 5000 | 428 | 4572 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
| 79734 | 100 | 0 | 100 | Prospective Zika Screening and Longitudinal Sample Collection Protocol |
| 78138 | 300 | 140 | 160 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 78137 | 300 | 414 | -114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
| 74261 | 10000 | 0 | 10000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 68258 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 66495 | 200 | 225 | -25 | Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue |
| 63869 | 1 | 2 | -1 | Negative Material for Panel Member |
| 63868 | 1000 | 555 | 445 | Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau |
| 56717 | 20000 | 0 | 20000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples |
| 55075 | 10000 | 28 | 9972 | Beta HCG Matched Set Prospective Blood Collection Protocol |
| 54664 | 200 | 148 | 52 | Random Cadaveric Samples |
| 38626 | 300 | 143 | 157 | Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications: ·50 x Alcoholic liver disease ·30 x Autoimmune hepatitis ·30 x Fatty liver disease ·30 x Non-alcoholic Steatohepatitis (NASH) ·30 x Primary Biliary Cirrhosis (PBC) |
| 27615 | 15000 | 633 | 14367 | Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World |
| 26761 | 10000 | 482 | 9518 | HIV Positive Time Stability Whole Blood Collection Protocol |
| 10694 | 3000 | 2234 | 766 | HCV Longitudinal Prospective Blood Collection Protocol |
| 10693 | 3000 | 369 | 2631 | HBV Multi-Point Prospective Blood Collection Protocol |
| 8568 | 300 | 1649 | -1349 | Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV) |
BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.
You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.
